BIOMAT Database Logo BIOMAT Database Logo

Bevacizumab and Temozolomide Plus Radiation Regimen for Glioblastoma Multiforme. 2015

Matthew R Rutledge, and J Aubrey Waddell, and Dominic A Solimando
Chief, Hematology-Oncology Pharmacy Service, Department of Pharmacy, Madigan Army Medical Center , Tacoma, Washington . The opinions or assertions contained herein are the private views of the authors and are not to be construed as official or reflecting the views of the US Department of the Army or the Department of Defense.

The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases. Questions or suggestions for topics should be addressed to Dominic A. Solimando, Jr, President, Oncology Pharmacy Services, Inc., 4201 Wilson Blvd #110-545, Arlington, VA 22203, e-mail: OncRxSvc@comcast.net; or J. Aubrey Waddell, Professor, University of Tennessee College of Pharmacy; Oncology Pharmacist, Pharmacy Department, Blount Memorial Hospital, 907 E. Lamar Alexander Parkway, Maryville, TN 37804, e-mail: waddfour@charter.net.

UI MeSH Term Description Entries

Related Publications

Matthew R Rutledge, and J Aubrey Waddell, and Dominic A Solimando
Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme.
January 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Matthew R Rutledge, and J Aubrey Waddell, and Dominic A Solimando
Complete remission after bevacizumab plus temozolomide in a patient with recurrent glioblastoma multiforme.
April 2012, Acta oncologica (Stockholm, Sweden),
Matthew R Rutledge, and J Aubrey Waddell, and Dominic A Solimando
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
February 2014, The New England journal of medicine,
Matthew R Rutledge, and J Aubrey Waddell, and Dominic A Solimando
AVAglio: Phase 3 trial of bevacizumab plus temozolomide and radiotherapy in newly diagnosed glioblastoma multiforme.
April 2011, Advances in therapy,
Matthew R Rutledge, and J Aubrey Waddell, and Dominic A Solimando
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.
October 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Matthew R Rutledge, and J Aubrey Waddell, and Dominic A Solimando
Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: a phase I study.
June 2010, Neuro-oncology,
Matthew R Rutledge, and J Aubrey Waddell, and Dominic A Solimando
Concurrent bevacizumab and temozolomide alter the patterns of failure in radiation treatment of glioblastoma multiforme.
April 2013, Radiation oncology (London, England),
Matthew R Rutledge, and J Aubrey Waddell, and Dominic A Solimando
Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide.
March 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
Matthew R Rutledge, and J Aubrey Waddell, and Dominic A Solimando
Trans sodium crocetinate with temozolomide and radiation therapy for glioblastoma multiforme.
February 2017, Journal of neurosurgery,
Matthew R Rutledge, and J Aubrey Waddell, and Dominic A Solimando
Patterns of failure for glioblastoma multiforme following concurrent radiation and temozolomide.
February 2011, Journal of medical imaging and radiation oncology,
Copied contents to your clipboard!